

DEC 30 2002

510(k) SUMMARY—ACell UBM Hydrated Wound Dressing

Submitter Name: ACell, Incorporated

Submitter Address: 10555 Guilford Road  
Suite 113  
Jessup, Maryland 20790

Contact Person: James R. DeFrancesco  
Chief Executive Officer

Phone Number: 410-715-1700

Fax Number: 301-317-0776

Date Prepared: August 15, 2002

Device Trade Name: ACell UBM Hydrated Wound Dressing

Device Common Name: Topical Wound Dressing

Classification Name: Bandage, Liquid (79KMF)

Predicate Devices: K993948, Cook Biotech, Inc., SIS Wound Dressing II  
K943781, AcryMed, Inc., AcryDerm® Advanced Wound Dressing

Device Description: The ACell UBM Hydrated Wound Dressing is primarily composed of porcine collagen and is supplied sterile in single sheet sizes ranging from 2 x 4 cm to 14 x 20 cm

Intended Use: The ACell UBM Hydrated Wound Dressing is intended for the management of wounds including: partial and full-thickness wounds, pressure ulcers, venous ulcers, diabetic ulcers, chronic vascular ulcers, tunneled/undermined wounds, surgical wounds (donor sites/grafts, post-Moh's surgery, post-laser surgery, podiatric, wound dehiscence), trauma wounds (abrasions, lacerations, second-degree burns, and skin tears), and draining wounds. The device is intended for one-time use.

000032

Sponsor:  
**ACell, Inc.**

Discussion of tests  
and test results.

The ACell UBM Hydrated Wound Dressing was subjected to a number of tests to assess the biocompatibility and the performance of the material. It passed the requirements of all tests and was shown to be safe and effective as a wound dressing.

Conclusion:

This device, with respect to material composition, device characteristics and intended use, is substantially equivalent to the predicate devices.



DEC 30 2002

Food and Drug Administration  
9200 Corporate Boulevard  
Rockville MD 20850

ACell, Inc.  
c/o Patsy J. Trisler, J.D., RAC  
Senior Director, Medical Device Consulting  
PharmaNet, Inc.  
815 Connecticut Avenue, NW, Suite 610  
Washington, D.C. 20006

Re: K022854

Trade/Device Name: ACell UBM Hydrated Wound Dressing  
Regulatory Class: Unclassified  
Product Code: KGN  
Dated: November 22, 2002  
Received: November 25, 2002

Dear Ms. Trisler:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

Page 2 - Patsy J. Trisler, J.D., RAC

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (301) 594-4659. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address <http://www.fda.gov/cdrh/dsma/dsmamain.html>

Sincerely yours,



for Celia M. Witten, Ph.D., M.D.  
Director  
Division of General, Restorative  
and Neurological Devices  
Office of Device Evaluation  
Center for Devices and  
Radiological Health

Enclosure

Sponsor:  
ACell, Inc.

ACell UBM Hydrated Wound Dressing  
Traditional 510(k) Premarket Notification

510(k) Number (if known):

K022854

Device Name:

ACell UBM Hydrated Wound Dressing

**Indications for Use:**

The ACell UBM Hydrated Wound Dressing is intended for the management of wounds including: partial and full-thickness wounds, pressure ulcers, venous ulcers, diabetic ulcers, chronic vascular ulcers, tunneled/undermined wounds, surgical wounds (donor sites/grfts, post-Moh's surgery, post-laser surgery, podiatric, wound dehiscence), trauma wounds (abrasions, lacerations, second-degree burns, and skin tears), and draining wounds. The device is intended for one-time use.

(PLEASE DO NOT WRITE BELOW THIS LINE – CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH; Office of Device Evaluation (ODE)

Prescription Use  (Per 21 CFR 801.109)

OR

Over-The-Counter Use

*Miriam C. Furoid*  
Division of  
and Neuro

(Optional Format 1-2-96)

K022854